Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

Affiliations

• ¹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bicarter@mdanderson.org.
• ² Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁴ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
• ⁶ Oncology Research, Amgen Inc, Thousand Oaks, CA, USA.
• ⁷ Amgen Inc, Thousand Oaks, CA, USA.
• ⁸ MLL Munich Leukemia Laboratory, Munich, Germany.
• ⁹ Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org.